Figure 3

Clinical trial study. (A) Scheme of the double-blind, placebo-controlled, randomized, cross-over (2 × 2) clinical trial. (B) Urticaria activity score (UAS), (C) Chronic Urticaria Quality of Life (CU-Q2oL) score, and (D) Visual Activity Scale (VAS) score reported by patients before the start of the study and after the two treatment periods (weeks 0, 18 and 40, respectively). The first three bars represent the patients who received OmAb followed by placebo (Arm A/A’), and the second three bars represent the patients who received placebo followed by OmAb (Arm B/B’). The box plots represent the median, 25th percentile and 75th percentile of UAS/CU-Q2oL/VAS scores of 17 patients enrolled in the clinical trial before and after receiving OmAb or placebo. The outer point corresponds to a patient who did not respond to the OmAb treatment. The Wilcoxon matched-pairs signed-rank test was used to evaluate differences between the values at baseline and at the end of the study (*p < 0.05).